Functional dyspepsia

New England Journal of Medicine

Volumn 373, Issue 19, 2015, Pages 1853-1863

  Talley, Nicholas J ^a   Ford, Alexander C ^b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACOTIAMIDE; AMITRIPTYLINE; ANTACID AGENT; BISMUTH; BUSPIRONE; CAPSAICIN; CISAPRIDE; DOMPERIDONE; ESCITALOPRAM; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IBEROGAST; ITOPRIDE; METOCLOPRAMIDE; MIRTAZAPINE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; SERTRALINE; SUCRALFATE; TANDOSPIRONE; UNCLASSIFIED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ABDOMINAL DISTENSION; ACUPUNCTURE; ALTERNATIVE MEDICINE; ANXIETY; BREATH ANALYSIS; CLINICAL FEATURE; CONSULTATION; DIET RESTRICTION; DISEASE CLASSIFICATION; DISEASE DURATION; DISTRESS SYNDROME; DRUG EFFICACY; DRUG FATALITY; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; ESOPHAGOGASTRODUODENOSCOPY; FECES ANALYSIS; HELICOBACTER PYLORI; HOMEOPATHY; HUMAN; LOW FAT DIET; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REASSURANCE; REVIEW; SATIETY; STRESS MANAGEMENT; TARDIVE DYSKINESIA; ALGORITHM; HELICOBACTER INFECTIONS; PATHOPHYSIOLOGY;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; PSYCHOTHERAPY;

EID: 84946600404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1501505     Document Type: Review

References (81)

1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
2. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: A metaanalysis. Gut 2015; 64: 1049-57.
3. Ford AC, Forman D, Bailey AG, Cook MB, Axon ATR, Moayyedi P. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007; 102: 957-65.
4. Sander GB, Mazzoleni LE, Francesconi CF, et al. Influence of organic and functional dyspepsia on work productivity: The HEROES-DIP study. Value Health 2011; 14: Suppl 1: S126-S129.
5. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: The economic impact to patients. Aliment Pharmacol Ther 2013; 38: 170-7.
6. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology 2014; 146: 932-40.
7. Fang YJ, Liou JM, Chen CC, et al. Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria. Gut 2015; 64: 1517-28.
8. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2010; 8: 830-7.
9. Ford AC, Ching E, Moayyedi P. Metaanalysis: Yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Ther 2009; 30: 28-36.
10. Hallas J, Bytzer P. Screening for drug related dyspepsia: An analysis of prescription symmetry. Eur J Gastroenterol Hepatol 1998; 10: 27-32.
11. Vakil N, Talley NJ, van Zanten SV, et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol 2009; 7: 756-61.
12. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80.
13. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: Systematic review and metaanalysis. Gastroenterology 2006; 131: 390-401.
14. Pleyer C, Bittner H, Locke GR III, et al. Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community. Neurogastroenterol Motil 2014; 26: 1163-71.
15. Vakil N, Halling K, Ohlsson L, Wernersson B. Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol 2013; 108: 767-74.
16. Pauwels A, Altan E, Tack J. The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastroesophageal reflux disease. Neurogastroenterol Motil 2014; 26: 581-8.
17. Matsuzaki J, Suzuki H, Asakura K, et al. Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil 2012; 24(4): 325-e164.
18. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 783-8.
19. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011; 140: 101-15.
20. Stanghellini V, Tack J. Gastroparesis: Separate entity or just a part of dyspepsia? Gut 2014; 63: 1972-8.
21. Heikkinen M, Räsänen H, Färkkilä M. Clinical value of ultrasound in the evaluation of dyspepsia in primary health care. Scand J Gastroenterol 2005; 40: 980-4.
22. Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 2008; 57: 1495-503.
23. Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: A factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21: 378-88.
24. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: Results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3: 543-52.
25. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: An endoscopic study. Gastroenterology 2010; 138: 1302-11.
26. van Kerkhoven LA, Laheij RJ, Meineche-Schmidt V, Veldhuyzen-van Zanten SJ, de Wit NJ, Jansen JB. Functional dyspepsia: Not all roads seem to lead to Rome. J Clin Gastroenterol 2009; 43: 118-22.
27. Aro P, Talley NJ, Johansson SE, Agréus L, Ronkainen J. Anxiety is linked to new-onset dyspepsia in the Swedish population: A 10-year follow-up study. Gastroenterology 2015; 148: 928-37.
28. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective population-based study. Gut 2012; 61: 1284-90.
29. Vandenberghe J, Dupont P, Van Oudenhove L, et al. Regional cerebral blood flow during gastric balloon distention in functional dyspepsia. Gastroenterology 2007; 132: 1684-93.
30. Wilder-Smith CH, Li X, Shen L, Cao Y, Ho KY, Wong RK. Dysfunctional endogenous pain modulation in patients with functional dyspepsia. Neurogastroenterol Motil 2014; 26: 489-98.
31. Oshima T, Toyoshima F, Nakajima S, Fukui H, Watari J, Miwa H. Genetic factors for functional dyspepsia. J Gastroenterol Hepatol 2011; 26: Suppl 3: 83-7.
32. Carbone F, Tack J. Gastroduodenal mechanisms underlying functional gastric disorders. Dig Dis 2014; 32: 222-9.
33. Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116: 515-20.
34. Futagami S, Itoh T, Sakamoto C. Systematic review with meta-Analysis: Postinfectious functional dyspepsia. Aliment Pharmacol Ther 2015; 41: 177-88.
35. Spiller R. Postinfectious functional dyspepsia and postinfectious irritable bowel syndrome: Different symptoms but similar risk factors. Gastroenterology 2010; 138: 1660-3.
36. Walker MM, Aggarwal KR, Shim LS, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol 2014; 29: 474-9.
37. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol 2010; 105: 1835-42.
38. Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: An adult endoscopic populationbased case-control study. Clin Gastroenterol Hepatol 2007; 5: 1175-83.
39. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 2014; 63: 262-71.
40. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106: 1089-98.
41. Azpiroz F, Feinle-Bisset C, Grundy D, Tack J. Gastric sensitivity and reflexes: Basic mechanisms underlying clinical problems. J Gastroenterol 2014; 49: 206-18.
42. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for nonulcer dyspepsia. Cochrane Database Syst Rev 2006; 2: CD002096 [Withdrawn: Cochrane Database Syst Rev 2011 February 16].
43. Walker MM, Talley NJ. Review article: Bacteria and pathogenesis of disease in the upper gastrointestinal tract -beyond the era of Helicobacter pylori. Aliment Pharmacol Ther 2014; 39: 767-79.
44. Farré R, Vanheel H, Vanuytsel T, et al. In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. Gastroenterology 2013; 145: 566-73.
45. Bharucha AE, Camilleri M, Burton DD, et al. Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia. Am J Gastroenterol 2014; 109: 1910-20.
46. Feinle-Bisset C, Azpiroz F. Dietary lipids and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108: 737-47.
47. Zuo XL, Li YQ, Li WJ, et al. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy 2007; 37: 823-30.
48. Walker MM, Powell N, Talley NJ. Atopy and the gastrointestinal tract -A review of a common association in unexplained gastrointestinal disease. Expert Rev Gastroenterol Hepatol 2014; 8: 289-99.
49. Friesen CA, Schurman JV, Colombo JM, Abdel-Rahman SM. Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia. World J Gastrointest Pharmacol Ther 2013; 4: 86-96.
50. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; 4: CD001960.
51. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5(12): E15591.
52. van Kerkhoven LA, van Rossum LG, van Oijen MG, Tan AC, Laheij RJ, Jansen JB. Upper gastrointestinal endoscopy does not reassure patients with functional dyspepsia. Endoscopy 2006; 38: 879-85.
53. Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 2000; 95: 1448-55.
54. Moayyedi P, Soo S, Deeks JJ, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000; 321: 659-64.
55. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171: 1929-36.
56. Lan L, Yu J, Chen YL, et al. Symptombased tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011; 17: 3242-7.
57. Iwakiri R, Tominaga K, Furuta K, et al. Randomised clinical trial: Rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther 2013; 38: 729-40.
58. Thumshirn M, Camilleri M, Saslow SB, Williams DE, Burton DD, Hanson RB. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 1999; 44: 55-64.
59. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: Results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57: 740-6.
60. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: Management of gastroparesis. Am J Gastroenterol 2013; 108: 18-37.
61. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: Randomized controlled study evaluation by real-Time ultrasonography. Neurogastroenterol Motil 2012; 24: 540-5.
62. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012; 61: 821-8.
63. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10: 1239-45.
64. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: A randomized controlled trial. Am J Gastroenterol 2009; 104: 2779-87.
65. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: A randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6: 746-52.
66. Tan VP, Cheung TK, Wong WM, Pang R, Wong BC. Treatment of functional dyspepsia with sertraline: A double-blind randomized placebo-controlled pilot study. World J Gastroenterol 2012; 18: 6127-33.
67. Ly HG, Carbone F, Holvoet L, et al. Mirtazapine improves early satiation, nutrient intake, weight recovery and quality of life in functional dyspepsia with weight loss: A double-blind, randomized, placebocontrolled pilot study. Gastroenterology 2013; 144: S37.
68. Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: A multi-center, randomized, controlled study. Gastroenterology 2015; 149: 340-9.
69. Soo S, Moayyedi P, Deeks JJ, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; 2: CD002301.
70. Orive M, Barrio I, Orive VM, et al. A randomized controlled trial of a 10-week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia. J Psychosom Res 2015; 78: 563-8.
71. Lahner E, Bellentani S, Bastiani RD, et al. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. United European Gastroenterol J 2013; 1: 385-93.
72. Lacy BE, Yu J, Crowell MD. Medication risk-Taking behavior in functional dyspepsia patients. Clin Transl Gastroenterol 2015; 6: E69.
73. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: Results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102: 1268-75.
74. Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1276-83.
75. Bortolotti M, Coccia G, Grossi G, Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002; 16: 1075-82.
76. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. Clin Gastroenterol Hepatol 2011; 9: 410-4.
77. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Effect of dyspepsia on survival: A longitudinal 10-year follow-up study. Am J Gastroenterol 2012; 107: 912-21.
78. Törnblom H, Drossman DA. Centrally targeted pharmacotherapy for chronic abdominal pain. Neurogastroenterol Motil 2015; 27: 455-67.
79. Arienti V, Corazza GR, Sorge M, et al. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994; 8: 631-8.
80. Drossman D, Szigethy E. The narcotic bowel syndrome: A recent update. Am J Gastroenterol 2014; 2: 22-30.
81. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Bjornsson E, Thjodleifsson B. Natural history of functional gastrointestinal disorders: Comparison of two longitudinal population-based studies. Dig Liver Dis 2012; 44: 211-7.